

Clinical trials of dofetilide

TrialResults-center www.trialresultscenter.org

1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
dofetilide vs placebo			
DIAMOND MI , 1997 n=NA follow-up: >12 months	dofetilide versus placebo	patients with acute myocardial infarction within 7 days and left ventricular systolic dysfunction (EF <= 35%)	Parallel groups double blind Danish

More details and results :

- antiarrhythmic drugs for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q130>

References

DIAMOND MI, 1997:

Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Danish Investigations of Arrhythmia and Mortality ON Dofetilide. Clin Cardiol 1997;20:704-10 [[9259163](#)]

2 post myocardial infarction

Trial	Treatments	Patients	Trials design and methods
dofetilide vs placebo			
DIAMOND MI , 1997 n=NA follow-up: >12 months	dofetilide versus placebo	patients with acute myocardial infarction within 7 days and left ventricular systolic dysfunction (EF <= 35%)	Parallel groups double blind Danish

More details and results :

- antiarrhythmic drugs for post myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q251>

References

DIAMOND MI, 1997:

Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Danish Investigations of Arrhythmia and Mortality ON Dofetilide. Clin Cardiol 1997;20:704-10 [9259163]

3 atrial fibrillation

Trial	Treatments	Patients	Trials design and methods
dofetilide vs placebo			
DIAMOND , 2001 n=249/257 follow-up: 24 months	Dofetilide 500 mcg/d5 versus placebo	Persistent AF in patients with heart failure or recent myocardial infarction and reduced LVEF	Parallel groups double blind
SAFIRE-D , 2000 n=182/68 follow-up: 12 months	Dofetilide various doses (250, 500, 1000 mcg/d) versus placebo	Persistent AF or AF1 lasting 2 weeks to 6 months	Parallel groups double blind

More details and results :

- antiarrhythmic drugs for atrial fibrillation in maintaining sinus rhythm after cardioversion at <http://www.trialresultscenter.org/go-Q113>

References

DIAMOND, 2001:

Mller M, Torp-Pedersen CT, Kber L Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Congest Heart Fail 2001;7:146-150 [11828153]

Torp-Pedersen C, Mller M, Bloch-Thomsen PE, Kber L, Sande E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999;341:857-65 [10486417]

Torp-Pedersen CT, Mller M, Bloch-Thomsen PE, Kber L, Sande E, Egstrup K, Agner E, Carlsen JE, Videbaek J [Dofetilide to patients with heart failure and left ventricular dysfunction] Ugeskr Laeger 2000;162:5948-53 [11094565]

SAFIRE-D, 2000:

Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, Billing CB Jr Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000;102:2385-90 [11067793]

Entry terms: dofetilide, 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane, 1-MSPMPE, Tikosyn, UK 68798,